Literature DB >> 25803559

Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes.

Malin Darnell, Katarina Breitholtz, Emre M Isin, Ulrik Jurva, Lars Weidolf.   

Abstract

Xenobiotic carboxylic acids may be metabolized to oxidative metabolites, acyl glucuronides, and/or S-acyl-CoA thioesters (CoA conjugates) in vitro, e.g., in hepatocytes, and in vivo. These metabolites can potentially be reactive species and bind covalently to tissue proteins and are generally considered to mediate adverse drug reactions in humans. Acyl glucuronide metabolites have been the focus of reactive metabolite research for decades, whereas drug-CoA conjugates, which have been shown to be up to 40-70 times more reactive, have been given much less attention. In an attempt to dissect the contribution of different pathways to covalent binding, we utilized human liver microsomes supplemented with NADPH, uridine 5'-diphosphoglucuronic acid (UDPGA), or CoA to evaluate the reactivity of each metabolite separately. Seven carboxylic acid drugs were included in this study. While ibuprofen and tolmetin are still on the market, ibufenac, fenclozic acid, tienilic acid, suprofen, and zomepirac were stopped before their launch or withdrawn. The reactivities of the CoA conjugates of ibuprofen, ibufenac, fenclozic acid, and tolmetin were higher compared to those of their corresponding oxidative metabolites and acyl glucuronides, as measured by the level of covalent binding to human liver microsomal proteins. The highest covalent binding was observed for ibuprofenyl-CoA and ibufenacyl-CoA, to levels of 1000 and 8600 pmol drug eq/mg protein, respectively. In contrast and in agreement with the proposed P450-mediated toxicity for these drug molecules, the reactivities of oxidative metabolites of suprofen and tienilic acid were higher compared to the reactivities of their conjugated metabolites, with NADPH-dependent covalent binding of 250 pmol drug eq/mg protein for both drugs. The seven drugs all formed UDPGA-dependent acyl glucuronides, but none of these resulted in covalent binding. This study shows that, unlike studies with hepatocytes or in vivo, human liver microsomes provide an opportunity to investigate the reactivity of individual metabolites.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25803559     DOI: 10.1021/tx500514z

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

1.  Benzoyl-CoA conjugate accumulation as an initiating event for male reprotoxic effects in the rat? Structure-activity analysis, species specificity, and in vivo relevance.

Authors:  Heike Laue; Remo P Badertscher; Lu Hostettler; Yumiko Weiner-Sekiya; Tina Haupt; Adrian Nordone; Gregory M Adamson; Andreas Natsch
Journal:  Arch Toxicol       Date:  2020-10-15       Impact factor: 5.153

2.  Defining Metabolic and Nonmetabolic Regulation of Histone Acetylation by NSAID Chemotypes.

Authors:  Jonathan H Shrimp; Julie M Garlick; Tugsan Tezil; Alexander W Sorum; Andrew J Worth; Ian A Blair; Eric Verdin; Nathaniel W Snyder; Jordan L Meier
Journal:  Mol Pharm       Date:  2017-12-29       Impact factor: 4.939

3.  Biomonitoring Human Albumin Adducts: The Past, the Present, and the Future.

Authors:  Gabriele Sabbioni; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2016-12-18       Impact factor: 3.739

4.  The metabolic fate of fenclozic acid in chimeric mice with a humanized liver.

Authors:  Anja Ekdahl; Lars Weidolf; Matthew Baginski; Yoshio Morikawa; Richard A Thompson; Ian D Wilson
Journal:  Arch Toxicol       Date:  2018-08-09       Impact factor: 5.153

5.  New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation.

Authors:  Mithat Gunduz; Upendra A Argikar; Amanda L Cirello; Jennifer L Dumouchel
Journal:  Drug Metab Lett       Date:  2018

6.  An adverse outcome pathway for immune-mediated and allergic hepatitis: a case study with the NSAID diclofenac.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Jürgen Borlak
Journal:  Arch Toxicol       Date:  2020-05-05       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.